The Intricate Expression of CC Chemokines in Glial Tumors: Evidence for Involvement of CCL2 and CCL5 but Not CCL11

• Main Authors: Mozhgan Moogooei, Masoud Shamaei, Hossein Khorramdelazad, Shirin Fattahpour, Seyed Mohammad Seyedmehdi, Maryam Moogooei, Gholamhossein Hassanshahi, Behjat Kalantari Khandani
• Format: Article
• Language: English
• Published: Tehran University of Medical Sciences 2015-12-01
• Series: Acta Medica Iranica
• Subjects: Glioblastoma; Anaplastic astrocytoma; Chemokine
• Online Access: https://acta.tums.ac.ir/index.php/acta/article/view/5296
• ISSN: 0044-6025; 1735-9694

Chemokines are biologically active peptides involved in the pathogenesis of various pathologies including brain malignancies. They are amongst primitive regulators of the development of immune responses against malignant glial tumors. The present study aimed to examine the expression of CC chemokines in anaplastic astrocytoma and glioblastoma multiform patients at both mRNA and protein levels. Blood specimens in parallel with stereotactic biopsy specimens were obtained from 123 patients suffering from glial tumors and 100 healthy participants as a control. The serum levels of CCL2, CCL5, and CCL11 were measured by ELISA and stereotactic samples subjected to western and northern blotting methods for protein and mRNA, respectively. Demographic characteristics were also collected by a researcher-designed questionnaire. Results of the present study indicated that, however,CCL2 andCCL5 are elevated in serum and tumor tissues of patients suffering from a glial tumor at both mRNA and protein levels, theCCL11 was almost undetectable. According to the findings of the present investigation, it could presumably be reasonable to conclude that chemokines are good predictive molecules for expecting disease severity, metastasis, and response to treatment.